Abstract. Limited clinical information is specified in the presentations, results of treatment and prognostic factors of follicular thyroid carcinoma with lung metastases. In order to better characterize the information, we retrospectively analyzed the data of 2,003 thyroid cancer patients who received treatment and follow-up at the Chang Gung Memorial Hospital during the period from January 1979 to December 2002. There were 1,516 cases of papillary and 272 cases of follicular thyroid carcinomas. In the study, lung metastases of the follicular thyroid carcinomas were defined as postoperative or follow-up chest X-ray, diagnostic or therapeutic 131 I scan with positive finding of lung metastases. Serum thyroglobulin (Tg) levels under thyroxine treatment of patients with lung metastases had to be over 1.5 ng/mL. Of the follicular thyroid carcinomas, there were 70 (25.7%) with lung metastases including 50 females (mean age 54.1 ± 12.6 years old) and 20 males (mean age 59.4 ± 12.0 years old). Of the 70 patients, there were 53 patients (75.7%) who presented with lung metastases at the time of diagnosis. Of the 70 patients of follicular thyroid carcinoma with lung metastases, 30 patients (42.9%) died at the end of the follow-up, and only 4 patients improved to disease free status. The 5, 10, 15, and 20 year survival rates in these patients were 68.5%, 54.0%, 41.6%, 27.7%, respectively. Age, post-operative Tg level and tumor size are important prognostic factors which are demonstrated to be significantly different statistically between lung metastases group and the group of the patients without distant metastasis. Otherwise, only the tumor size and accumulative dose of 131 I therapy demonstrate a significant difference between survival and mortality groups. Seventeen of the 70 patients developed lung metastases during the follow-up period. Mean period between diagnosis and recurrence of these patients was 3.6 ± 0.9 years. Over 75% of follicular thyroid carcinoma with lung metastases was diagnosed at the time of presentation. Forty percent (28/70 cases) of the follicular thyroid carcinoma with lung metastases had history of thyroid surgery in this study. If lung metastases are diagnosed in follicular thyroid carcinoma, it will be followed by a poor prognosis. Older patients, higher postoperative Tg, and larger tumor size in follicular thyroid carcinoma need aggressive postoperative treatment. MOST well differentiated thyroid cancer cases progress slowly in their clinical courses [1] [2] [3] . Around 8 to 33% of the follicular thyroid carcinoma patients presented with distant metastases at the time of diagnosis [4] [5] [6] . In our recent study, 33.7% of the follicular thyroid cancer cases presented with distant metastases during the follow-up period [7] . When comparing the clinical presentations of the follicular thyroid cancer with other series, a relatively high incidence of the distant metastases was noted [3, 6, 7] . Hematogenous spreading had been known as the main way of distant metastases in follicular thyroid carcinoma. There are a few reports on clinical analysis for the survival of well-differentiated thyroid cancer with distant metastases including lung metastases [8] [9] [10] ; otherwise, few reports describe lung metastases of the follicular thyroid carcinoma at the initial presentation or followup period. Respiratory insufficiency due to remark-
MOST well differentiated thyroid cancer cases progress slowly in their clinical courses [1] [2] [3] . Around 8 to 33% of the follicular thyroid carcinoma patients presented with distant metastases at the time of diagnosis [4] [5] [6] . In our recent study, 33.7% of the follicular thyroid cancer cases presented with distant metastases during the follow-up period [7] . When comparing the clinical presentations of the follicular thyroid cancer with other series, a relatively high incidence of the distant metastases was noted [3, 6, 7] . Hematogenous spreading had been known as the main way of distant metastases in follicular thyroid carcinoma. There are a few reports on clinical analysis for the survival of well-differentiated thyroid cancer with distant metastases including lung metastases [8] [9] [10] ; otherwise, few reports describe lung metastases of the follicular thyroid carcinoma at the initial presentation or followup period. Respiratory insufficiency due to remark-able pulmonary metastasis replacing lung tissue and massive hemorrhage were the most common specific fatal conditions in thyroid cancer [11] . Despite the poor prognosis of these patients [12] , the characteristics of these thyroid follicular carcinoma patients presenting with lung metastases need further investigation. Clinical features and prognosis of the follicular thyroid carcinoma are quite different from papillary thyroid carcinoma. For these reasons, we need more data about the long-term follow-up of follicular thyroid cancer with lung metastasis in order to analyze various clinical factors, and to determine the best modality of treatment.
Materials and Methods
For the data on thyroid cancer patients who were treated in Chang Gung Medical Center, thyroid cancer patients were selected from the medical records, and all patients who did not receive regular follow-up were contacted by telephone. Pathological review was performed for all thyroid carcinomas according to the World Health Organization (WHO) classification [13] . Finally, a total of 2,003 pathologically verified thyroid cancer patients were complied by the end of 2002. Among these cases, 1,778 had been diagnosed with papillary or follicular thyroid carcinoma. Of these, 15.2% (272 cases) had follicular thyroid carcinoma. In this study, tumor staging was classified according to the clinical staging as previously described [14] . Stage I is a tumor with a single or multiple intrathyroidal foci. Stage II is a tumor with cervical metastases. Stage III is a thyroid tumor with local cervical invasion or fixed cervical metastases. Stage IV is lesions metastatic outside of the neck. All the patients were categorized as either disease free or non-disease free after treatment at the end of 2002. Till the end of the follow-up date, there were 66 follicular thyroid carcinoma patients with lung metastases diagnosed by radioactive iodide ( 131 I), chest X-ray or CT imaging studies.
In the study, lung metastases of the follicular thyroid carcinomas were defined as post-operative or followup chest X-ray, diagnostic or therapeutic 131 I scan with positive finding of lung metastases. Serum thyroglobulin (Tg) levels under thyroxine treatment of the patients with lung metastases had to be over 1.5 ng/mL or demonstrated histologically. After the operation, either 131 I therapy with a dose of 100 to 150 mCi or external radiotherapy were suggested, and patients received long-term thyroid hormone suppressive treatment. Regular check-ups including 2 to 5 mCi 131 I whole body scan, chest X-ray and serum thyroglobulin (Tg), were performed every 6 to 12 months. Most thyroid cancer patients received regular follow-ups at the Metabolic Division of the Chang Gung Medical Center. Hospital records were reviewed and the following data were stored in computer: age, gender, pre-operative ultrasonographic findings, fine needle aspiration cytological (FNAC) results, thyroid function, results of thyroid scanning, histopathological type, primary tumor size, methods of operation, post-operative serum Tg levels, results of post-operative 2 to 5 mCi of 131 I cancer work-up, chest X-ray findings, CT scans, follow-up status, sites of metastases, survival, and follow-up period.
For the comparison 70 follicular thyroid carcinoma with lung metastases were compared with 163 patients with follicular thyroid carcinoma without evidence of distant metastasis during the follow-up period. Univariate statistical analysis of the significance of various factors was performed using the Kaplan-Meier method and the log-rank test [15, 16] . Statistical significance was accepted to correspond to a p value of less than or equal to 0.05. Actuarial survival rates were calculated by the Kaplan-Meier method and differences in survival rates were examined using the tests of Breslow and Mantel-Cox.
Results
There were 70 patients who were diagnosed as follicular thyroid carcinomas with lung metastases. Fig. 1 shows the age and gender distribution of the 163 patients with follicular thyroid carcinoma without distant metastasis and the 70 cases with lung metastases. Another 39 follicular thyroid cancer without lung metastases but with local or metastases to other sites were not included in the analysis. The peak age distributions of the female and male were 61-70 and 51-60 years old for the patients with lung metastases; otherwise, the peak ages in female and male were 21-40 years old for the female and 31-50 years old for male patients without distant metastasis. Of the 70 cases, there were 50 females with the mean age 54.1 ± 12.6 years old and 20 males with the mean age 59.4 ± 12.0 years old. Thirty-five of them received total thyroidectomy. Twenty-eight patients received subtotal or lobectomy surgical treatment. Another four patients received operation for the distant metastases including scalp and vertebra only. Table 1 shows the clinical presentations of 163 follicular thyroid carcinoma patients without metastasis and the 70 patients with lung metastases. Age, tumor size, post-operative Tg levels, and survival rate were important clinical prog- Biopsy + lob/subtotal/total thyroidectomy: biopsy or lobectomy/subtotal thyroidectomy/total thyroidectomy nostic factors demonstrating statistically significant differences between two groups. Of the 70 patients, 53 follicular thyroid carcinoma patients presented with lung metastases at the time of diagnosis. Of the 53 patients, 38 of them could be detected by chest X-ray or 131 I scans, and 15 of them could be detected by 131 I scans only. After treatment, 4 of them improved to disease free, and 49 of them remained in distant metastases status. Another 17 patients were diagnosed as lung metastases during the follow-up period either by chest X-ray or 131 I scans. Mean period between diagnosis and recurrence in these patients was 3.6 ± 0.9 years. Of the 70 follicular thyroid carcinomas with lung metastases, 56 received postoperative 131 I treatment for the remnant tissue ablation or distant metastases. Mean dose of 131 I was 383 ± 48 mCi (range 30 to 1,560 mCi). Thirty-two received external radiotherapy including 13 to neck and mediastinum and 19 for the distant metastatic area.
Mean follow up period of 233 follicular thyroid carcinoma patients was 6.3 years. After the treatment, 37 (15.9%) died including 30 of the 70 cases (42.9%) with lung metastases. Among these patients, the mean follow-up periods of non-metastatic and lung metastatic patients were 6.1 ± 0.3 years and 6.6 ± 0.7 years, respectively. The clinical information of 30 mortality cases are compared with survival patients with lung metastases in Table 2 . Age, gender, surgical methods, clinical stage at the time of diagnosis, and post-operative Tg levels revealed no statistically significant differences between the groups. Only the tumor size and followup period show statistically significant differences between these two groups. Of the 70 patients in this study, there were 28 patients who had prior history of thyroid operation at other hospitals from one to 27.3 years ago.
Half of these patients (14/28 cases) denied the history of thyroid malignancy in the first surgery for the goiter. Fig. 2 A shows Kaplan-Meier survival curves of the follicular thyroid carcinomas without distant metastasis and patients with lung metastases. The 5, 10, 15, and 20 year survival rates in both groups were 96.4%, 96.4%, 87.5%, 87.5% and 68.5%, 54.0%, 41.6%, 27.7%, respectively. Of the 70 cases, there were 54 cases with lung metastases only; otherwise 16 cases presented with other organs involvement. Further comparison of survival curves between the groups of lung metastases only with multi-organ metastases (Fig. 2B ) revealed no statistically significant difference of the mortality rates.
Discussion
Unlike papillary thyroid carcinoma, preoperative diagnosis of follicular thyroid carcinoma with FNAC is difficult [17, 19] . Capsule and vascular invasion are the main characteristic differences between thyroid follicular adenoma and carcinoma. These features could not be interpreted by pre-operative FNAC or other diagnostic tools. Although most follicular thyroid carcinoma with lung metastases follow the course of cancer cells spreading from thyroid cancer tissue, most cases in this study were diagnosed as lung metastases at the same time as thyroid cancer. Delayed diagnosis and misdiagnosis as benign thyroid follicular adenoma in previous surgical tissues or presentation of thyroid microcarcinoma are the main reasons. Bone and lung are the major targets of distant metastases by the thyroid follicular cells. Large perfusion area and high blood flow may be the main reasons. There are few reports of liver metastases of follicular thyroid cancer with histological evidence. The reason needs to be further investigated.
Surgical treatment for the metastatic lesions has been mentioned in the management of thyroid carcinoma [20, 21] . Intrathoracic metastatic thyroid malignancy is the main site of these patients. After metastasectomy, in the different study subjects the 5-year survival rate of these patients varies from 78.5% to 32.5%. The lung is the major organ to be involved by well-differentiated thyroid cancer. Open lung biopsy or metastatic single lung nodule has been performed in order to achieve a cure. Unfortunately, there are few patients with only one lesion in radiological studies with negative 131 I scanning of the lung in follicular thyroid cancer. For the diagnosis of lung metastases from follicular thyroid cancer, imaging-guided percutaneous fine-needle aspiration biopsy is a better way to avoid severe complications [22, 23] . In view of the cancer cell behavior with hematogenous spreading, it seems impossible to remove the single lung lesion to cure the follicular thyroid cancer with distant metastases [24] .
In our study, 53 (19.5%) of the 272 follicular thyroid carcinoma patients presented with lung metastases at the time of diagnosis. This ratio was much higher than that of papillary thyroid carcinoma of 3.4% (52 out of 1,516 cases) in our series. In contrast to papillary thyroid carcinoma, follicular thyroid carcinoma was characterized by spreading via blood vessels. In in vitro study, follicular thyroid cancer cells interact faster and more intensively with human endothelial cells than papillary thyroid carcinoma and follicular adenoma cells [25] .
In this series, over 75% of the follicular thyroid carcinoma with lung metastases were diagnosed at the time of follicular cancer. One of the main reasons is many thyroid cancers with distant metastases were referred to our medical center. Another reason, as stated in our previous report, is delayed diagnosis of follicular cancer which is an important issue in this area [26] . After aggressive treatment, the 5 and 10 year survival were 68.5%, and 54.0%, respectively. These results were close to recent studies after metastasectomy in the management of thyroid carcinoma [20] . There were discrepancies in the criteria of lung metastases, different follow-up procedures, and the varying ethnic, and geographic factors. Surgical treatment for distant metastases did not seem to improve the survival rate of these patients. The results of the treatment from our series and NIH are better than the reports of 15 years ago [20, 27] .
Most studies did not separate the survival rates of the lung metastases from bone metastases. Previous study suggested that bone metastases of well-differentiated thyroid carcinomas had worse prognosis than lung metastases [27] . The reasons for the difference in the prognosis were due to these two organs, different responses to 131 I therapy and the nature of their clinical courses. In our analysis, lung metastases are usually the first organ involved by follicular thyroid carcinoma with distant metastases. The survival analysis of follicular thyroid carcinomas with lung metastases only or multi-organ metastases demonstrated no difference. In the patients with lung and bone metastases, trapping 131 I in different organs depends on the concentration of the sodium iodide symporters and the differentiation of the cancer cells [28, 29] . Clinical data of follicular thyroid cancer in both conditions were noted as either presenting with lung metastases detected by 131 I and bone metastases detected by bone scan but not by 131 I, or presenting with bone metastases detected by 131 I scans and lung metastases by chest X-ray but not by 131 I scan. Early diagnosis of the thyroid malignancy followed by aggressive treatment and more close follow-up patients with follicular thyroid carcinoma are mandatory.
In conclusion, follicular thyroid cancer with lung metastases is a condition which has virtually the same prognosis as multi-organ metastases. Due to the fact that most patients are diagnosed at the time of thyroid operation, early diagnosis of thyroid follicular neoplasm is much needed in this area. High risk of the patients with older age, bigger tumor size or higher post-operative Tg level should be regarded as indications of this condition during the follow-up period.
